Literature DB >> 18310193

Risk factors for developing apnea after immunization in the neonatal intensive care unit.

Nicola P Klein1, Maria L Massolo, John Greene, Cornelia L Dekker, Steven Black, Gabriel J Escobar.   

Abstract

OBJECTIVES: Among hospitalized NICU infants, preimmunization apnea is a well-recognized predictor of postimmunization apnea. However, predictors for postimmunization apnea among NICU infants without preimmunization apnea have not been investigated.
METHODS: Using a large NICU database in the Northern California Kaiser Permanente Medical Care Program, we abstracted NICU charts of infants who were hospitalized for > or = 53 days and who were also immunized, capturing preimmunization (24 hours before immunization) and postimmunization (48 hours after immunization) events. We assessed factors associated with postimmunization apnea by using multivariate logistic regression.
RESULTS: Of 16,146 infants admitted to the NICU, 557 received > or = 1 vaccine and 497 met the criteria for study entry. All infants with preimmunization apnea (n = 27) and all except 3 infants with postimmunization apnea (n = 65) had gestational ages of < 31 weeks. Multivariate analyses revealed preimmunization apnea as the most important predictor of postimmunization apnea, although higher 12-hour Score for Neonatal Acute Physiology II and age of < 67 days (mean cohort age) were also associated. Multivariate analysis exclusively among infants without preimmunization apnea similarly found elevated Score for Neonatal Acute Physiology II, age of < 67 days, and weight of < 2000 g to be associated with postimmunization apnea. Forty-nine infants without preimmunization apnea and with > or = 1 apnea predictor were discharged within 48 hours after immunization; 2 were subsequently readmitted because of apnea.
CONCLUSIONS: For infants in the NICU without apnea during the 24 hours immediately before immunization, younger age, smaller size, and more severe illness at birth are important predictors of postimmunization apnea.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18310193     DOI: 10.1542/peds.2007-1462

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  7 in total

Review 1.  Immunization of preterm infants.

Authors:  Arnaud Gagneur; Didier Pinquier; Caroline Quach
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Vaccine schedule compliance among very low birth weight infants in Lima, Peru.

Authors:  Theresa J Ochoa; Alonso Zea-Vera; Rossana Bautista; Carmen Davila; José Antonio Salazar; Carlos Bazán; Luis López; Lucie Ecker
Journal:  Vaccine       Date:  2014-11-21       Impact factor: 3.641

3.  Adverse Events After Routine Immunization of Extremely Low-Birth-Weight Infants.

Authors:  Stephen D DeMeo; Sudha R Raman; Christoph P Hornik; Catherine C Wilson; Reese Clark; P Brian Smith
Journal:  JAMA Pediatr       Date:  2015-08       Impact factor: 26.796

4.  Impact of birthweight on health-care utilization during early childhood - a birth cohort study.

Authors:  Mario Rüdiger; Luise Heinrich; Katrin Arnold; Diana Druschke; Jörg Reichert; Jochen Schmitt
Journal:  BMC Pediatr       Date:  2019-03-01       Impact factor: 2.125

Review 5.  Hexavalent vaccines in preterm infants: an update by Italian Society of Pediatric Allergy and Immunology jointly with the Italian Society of Neonatology.

Authors:  E Chiappini; C Petrolini; C Caffarelli; M Calvani; F Cardinale; M Duse; A Licari; S Manti; A Martelli; D Minasi; M Miraglia Del Giudice; G B Pajno; C Pietrasanta; L Pugni; M A Tosca; F Mosca; G L Marseglia
Journal:  Ital J Pediatr       Date:  2019-11-19       Impact factor: 2.638

Review 6.  Frequently asked questions on seven rare adverse events following immunization.

Authors:  G L D'alò; E Zorzoli; A Capanna; G Gervasi; E Terracciano; L Zaratti; E Franco
Journal:  J Prev Med Hyg       Date:  2017-03

7.  Safety and immunogenicity of a fully-liquid DTaP-IPV-Hib-HepB vaccine (Vaxelis™) in premature infants.

Authors:  Marissa B Wilck; Z Jin Xu; Jon E Stek; Andrew W Lee
Journal:  Hum Vaccin Immunother       Date:  2020-08-04       Impact factor: 3.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.